Table 4 ORR for selected biomarker subgroups; modified full analysis set (N = 47).

From: Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Gene

Patients, n

Responses, n

ORR, % (90% CI)

TP53a

 Wild type

2

0

0.0 (0.0, 77.6)

 Mutant

34

9

26.5 (14.6, 41.6)

ARID1A

 Wild type

34

9

26.5 (14.6, 41.6)

 Mutant

2

0

0.0 (0.0, 77.6)

ATM

 Wild type

31

8

25.8 (13.5, 41.8)

 Mutant

5

1

20.0 (1.0, 65.7)

Germline BRCA1/2

 Wild type

31

7

22.6 (11.1, 38.3)

 Mutant

5

2

40.0 (7.6, 81.1)

Basal subtypeb

 Yes

36

9

25.0 (13.7, 39.6)

  1. ARID1A AT-rich interaction domain 1A, ATM ataxia-telangiectasia-mutated, BRCA1/2 breast cancer gene 1/2, CI confidence interval, ORR overall response rate, PAM50 Prediction Analysis of Microarray 50, TP53 tumor protein 53.
  2. aOnly patients with biomarker status determined by FoundationOne® CDx next-generation sequencing were reported.
  3. bBasal subtype was determined via PAM50 analysis (Prosigna) and was performed retrospectively.
Back to article page